David A. Siegel Inhibrx, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Inhibrx, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 282,000 shares of INBX stock, worth $4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

282,000

Previous 210,800 33.78%

Holding current value

$4 Million

Previous $8.01 Million 23.07%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $2.33 Million - $2.82 Million	71,200 Added 33.78%	282,000 $9.86 Million
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $1.44 Million - $3.78 Million	-99,400 Reduced 32.04%	210,800 $8.01 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $270,900 - $452,532	17,200 Added 5.87%	310,200 $5.69 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $323,936 - $531,362	19,100 Added 6.97%	293,000 $7.61 Million
Q1 2023 May 15, 2023	BUY	$18.45 - $27.14 $1.24 Million - $1.82 Million	67,100 Added 32.45%	273,900 $5.17 Million

Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $1.15 Million - $1.9 Million	57,000 Added 38.05%	206,800 $5.1 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $1.22 Million - $2.61 Million	105,600 Added 238.91%	149,800 $2.69 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $235,152 - $697,176	27,600 Added 166.27%	44,200 $502,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $330,174 - $716,788	16,600 New	16,600 $370,000
Q2 2021 Aug 16, 2021	SELL	$14.69 - $27.52 $154,245 - $288,960	-10,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $170,835 - $433,230	10,500 New	10,500 $211,000

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account